{
  "run_date": "2026-02-08T08:27:42.986194+00:00",
  "stocks_scanned": 235,
  "top_picks": [
    {
      "ticker": "TKA",
      "name": "thyssenkrupp AG",
      "exchange": "XETR",
      "index": "DAX",
      "sector": "Industrials",
      "price": 11.655,
      "currency": "EUR",
      "market_cap": 9659455488,
      "pe_ratio": 15.54,
      "forward_pe": 10.92704,
      "roe": 5.0869998,
      "dividend_yield": 129.0,
      "momentum_6m": 19.602403566203286,
      "momentum_12m": 157.50894348275168,
      "rsi_14": 66.40772694967322,
      "alpha_score": 82,
      "score_breakdown": {
        "value": 21,
        "quality": 15,
        "momentum": 25,
        "catalyst": 13,
        "liquidity": 8
      },
      "yahoo_url": "https://finance.yahoo.com/quote/TKA.DE",
      "signal": "BUY",
      "confidence": "MEDIUM",
      "reasoning": "Thyssenkrupp is a German industrial conglomerate undergoing significant transformation, with operations spanning steel, materials, and industrial services. The company has experienced substantial stock appreciation, more than doubling from approximately \u20ac4.00 in early 2025 to around \u20ac11.66 currently, though this reflects volatile price action amid restructuring execution and macroeconomic uncertainty[1]. The company is navigating a challenging industrial backdrop while implementing a major steel division restructuring.",
      "company_overview": "Thyssenkrupp is a German industrial conglomerate undergoing significant transformation, with operations spanning steel, materials, and industrial services. The company has experienced substantial stock appreciation, more than doubling from approximately \u20ac4.00 in early 2025 to around \u20ac11.66 currently, though this reflects volatile price action amid restructuring execution and macroeconomic uncertainty[1]. The company is navigating a challenging industrial backdrop while implementing a major steel division restructuring.",
      "key_developments": [
        "**Steel Restructuring Agreement**: Management and unions agreed in late 2025 to cut or outsource approximately 11,000 jobs and reduce production capacity in the steel division, with the restructuring program financed and scheduled to run until 2030[1]. This represents a fundamental shift in the company's operational footprint and cost structure."
      ],
      "catalysts": [
        "**Q1 FY2025/2026 Earnings Release (February 12, 2026)**: Detailed commentary on restructuring progress, cost savings realization, and updated full-year guidance will be essential for validating the investment thesis. Any acceleration in restructuring timelines or higher-than-expected cost savings could reignite momentum."
      ],
      "risk_factors": [
        "**Execution Risk on Restructuring**: The 11,000-job reduction and capacity cuts represent a complex, multi-year operational transformation. Delays, labor disputes, or higher-than-expected restructuring costs could erode shareholder value and extend the timeline to profitability improvement."
      ],
      "sources": [
        "https://capital.com/en-int/analysis/thyssenkrupp-stock-forecast",
        "https://www.thyssenkrupp.com/en/investors/calendar",
        "https://www.thyssenkrupp.com/en/investors",
        "https://www.thyssenkrupp.com/en/investors/reporting-and-publications",
        "https://www.marketscreener.com/quote/stock/THYSSENKRUPP-AG-436698/finances/",
        "https://simplywall.st/stocks/de/materials/etr-tka/thyssenkrupp-shares/past",
        "https://eulerpool.com/en/stock/thyssenkrupp-Stock-DE0007500001/NetIncome"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "EN",
      "name": "Bouygues SA",
      "exchange": "EPA",
      "index": "CAC40",
      "sector": "Industrials",
      "price": 48.25,
      "currency": "EUR",
      "market_cap": 18544437248,
      "pe_ratio": 17.545454,
      "forward_pe": 13.719469,
      "roe": 8.397,
      "dividend_yield": 415.00000000000006,
      "momentum_6m": 25.84767816372373,
      "momentum_12m": 60.73101046194995,
      "rsi_14": 69.28839450740628,
      "alpha_score": 78,
      "score_breakdown": {
        "value": 21,
        "quality": 9,
        "momentum": 25,
        "catalyst": 13,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/EN.PA",
      "signal": "HOLD",
      "confidence": "HIGH",
      "reasoning": "Bouygues demonstrates operational resilience with confirmed 2025 guidance and solid construction momentum, but recent profit softness and lack of major positive catalysts in the last 30 days limit upside potential amid European industrial sector headwinds.[1][2] The stock's high momentum (Alpha Score 78/100) and attractive valuation (P/E 14.49 trailing, 11.76 forward) support holding for dividend yield, though short-term technicals suggest controlled movements without strong buy signals.[1][2]",
      "company_overview": "Bouygues SA is a diversified French conglomerate operating in construction, telecommunications (Bouygues Telecom), and media, with a strong market position in Europe evidenced by \u20ac57.16B trailing twelve-month revenue and \u20ac1.05B net income.[2] The company reported robust nine-month 2025 results, with sales up 0.9% year-on-year despite a profit decline, while maintaining its full-year 2025 outlook for a slight increase in current operating profit (COPA) and sales at constant exchange rates.[2] Shares have delivered strong performance, with a 52-week high near current levels around \u20ac48.25 and a 5.02% dividend yield, supported by a low beta of 0.68 indicating relative stability.[2]",
      "key_developments": [
        "Issued monthly disclosure on February 2, 2026, reporting 385,439,418 total shares and 496,550,003 exercisable voting rights as of January 31, 2026, a routine update with no material impact.[4][5]",
        "Released nine-month 2025 results on November 5, 2025, showing strong construction sales growth and financial resilience amid challenges, with group sales up 0.9% but profit down; full-year outlook confirmed.[2]",
        "Reported first-half 2025 results with \u20ac26.9B sales (up 1.3%) and confirmed 2025 outlook in an uncertain macroeconomic environment; first-quarter sales also rose 2.2%.[2]"
      ],
      "catalysts": [
        "Q4/full-year 2025 earnings release and call, expected around late February 2026 (aligned with prior patterns like February 26 noted for prior year), potentially confirming outlook and providing 2026 guidance.[2]",
        "Potential dividend payment or ex-date announcement following May 2025 precedent, offering yield support in a high-interest-rate European context.[2]"
      ],
      "risk_factors": [
        "Macroeconomic and geopolitical uncertainty in Europe, as repeatedly flagged in earnings releases, could pressure construction and telecom margins.[2]",
        "Low trading volume divergence noted in recent sessions, increasing short-term volatility risk despite overall low-risk profile.[1]"
      ],
      "sources": [
        "https://stockinvest.us/stock/BOUYY",
        "https://stockanalysis.com/quote/epa/EN/",
        "https://www.investing.com/equities/bouygues-n",
        "https://live.euronext.com/en/products/equities/company-news/2026-02-02-bouygues-monthly-disclosure-total-number-shares-and",
        "https://www.globenewswire.com/news-release/2026/02/02/3230458/0/en/bouygues-monthly-disclosure-of-the-total-number-of-shares-and-voting-rights.html"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "AZN",
      "name": "AstraZeneca PLC",
      "exchange": "LSE",
      "index": "FTSE100",
      "sector": "Healthcare",
      "price": 14104.0,
      "currency": "GBP",
      "market_cap": 218651983872,
      "pe_ratio": 31.623316,
      "forward_pe": 18.686577,
      "roe": 21.674,
      "dividend_yield": 173.0,
      "momentum_6m": 27.799927509967382,
      "momentum_12m": 20.387470630408732,
      "rsi_14": 54.043839758125465,
      "alpha_score": 75,
      "score_breakdown": {
        "value": 5,
        "quality": 22,
        "momentum": 25,
        "catalyst": 13,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/AZN.L",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "AstraZeneca's NYSE listing enhances liquidity and investor access in the key US market, supporting its high momentum (Alpha Score 25/25) and quality (22/25) amid a strong pipeline with $10B+ peak revenue potential. The reiterated 2030 targets of $80B revenue signal sustained growth trajectory in a favorable healthcare sector, though premium valuation (P/E 31.6) tempers conviction without additional near-term catalysts detailed.[1]",
      "company_overview": "AstraZeneca PLC (AZN) is a global biopharmaceutical company focused on oncology, rare diseases, and bioPharmaceuticals, with a strong market position evidenced by recent robust growth and a harmonized global listing structure across NYSE, LSE, and Nasdaq Stockholm. The company trades ordinary shares on the NYSE under AZN, replacing prior American Depositary Shares, while maintaining its UK and Swedish listings unchanged. It reports strong momentum with key metrics including a P/E of 31.6, ROE of 21.7%, and 6-month return of +27.8%, alongside an Alpha Score of 75/100 driven by quality and momentum.[1]",
      "key_developments": [
        "AstraZeneca began trading ordinary shares on the NYSE under the AZN ticker, creating a harmonized global listing with LSE and Nasdaq Stockholm to access the world's largest capital market and broaden its investor base.[1]",
        "The company highlights recent pipeline readouts representing over $10 billion in peak revenue opportunity, underscoring strong growth momentum.[1]",
        "Management reiterated confidence in its 2030 ambition of $80 billion in annual revenue and launching 20 new medicines, with prior US ADS listing ceased and US dollar bonds transitioning to NYSE.[1]"
      ],
      "catalysts": [
        "Pipeline readouts from recent developments, potentially unlocking further revenue growth toward 2030 ambitions.[1]",
        "Expanded US investor participation following NYSE ordinary share trading debut, boosting liquidity and index inclusion potential.[1]"
      ],
      "risk_factors": [
        "Execution risks on ambitious 2030 goals ($80B revenue, 20 new medicines) amid competitive biopharma landscape and regulatory hurdles.[1]",
        "Valuation stretch at P/E 31.6, vulnerable to market rotations away from high-growth healthcare stocks.[1]"
      ],
      "sources": [
        "https://www.stocktitan.net/sec-filings/AZN/6-k-astrazeneca-plc-current-report-foreign-issuer-5cf8521c5fa8.html"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "DG",
      "name": "Vinci SA",
      "exchange": "EPA",
      "index": "CAC40",
      "sector": "Industrials",
      "price": 134.2,
      "currency": "EUR",
      "market_cap": 74474168320,
      "pe_ratio": 15.496535,
      "forward_pe": 13.201904,
      "roe": 15.713,
      "dividend_yield": 373.0,
      "momentum_6m": 8.321016006141392,
      "momentum_12m": 30.518547803182727,
      "rsi_14": 84.94207993778656,
      "alpha_score": 72,
      "score_breakdown": {
        "value": 21,
        "quality": 16,
        "momentum": 20,
        "catalyst": 5,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/DG.PA",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "Vinci demonstrated resilient 2025 performance with revenue/profit beats, record cash flow, and dividend hike amid global headwinds, positioning it for 2026 growth in revenue, earnings, and \u20ac6B+ free cash flow.[2][1] Strong cash generation and portfolio reviews signal financial flexibility, outweighing tax concerns, with recent momentum (9.91% daily gain, RSI 51.97) supporting upside from current \u20ac134.20 levels.[3][1]",
      "company_overview": "Vinci SA is a leading European construction and infrastructure company, operating in concessions (motorways, airports), energy, and construction segments, with a market cap of \u20ac67.63B and trailing revenue of \u20ac73.73B.[1] In 2025, it achieved revenue of \u20ac74.60B (up 4.2% YoY), net profit of \u20ac4.90B (up 0.8%), and record free cash flow of \u20ac7.01B, supporting a proposed dividend increase to \u20ac5/share.[2] The stock has surged recently, gaining 9.91% to \u20ac134.20 on February 6, 2026, amid a 52-week high near \u20ac134.75 and strong 12-month returns of +30.5%.[1][3][7]",
      "key_developments": [
        "Reported FY 2025 results on February 5-6, 2026: revenue beat estimates at \u20ac74.60B, EPS grew 12%, free cash flow hit record \u20ac7.01B (up from \u20ac6.81B), driving shares up 6.4% to \u20ac129.95 initially.[2][5][6]",
        "Nine-month 2025 revenues up 3.7% to \u20ac54.25B (2.0% like-for-like), with Q1 2025 revenue up 4% to \u20ac16.3B on solid concessions traffic.[1]",
        "BofA downgraded to Underperform citing French tax risks, muted 3.5% annual EBIT growth forecast for 2026-27, and expiring concessions impacting EBITDA by 2037.[4]"
      ],
      "catalysts": [
        "2026 guidance confirmation and Q1 results (expected April 2026), building on confident outlook for revenue/earnings growth.[2]",
        "Potential asset disposals from ongoing portfolio reviews in concessions, energy, and construction units.[2]"
      ],
      "risk_factors": [
        "French tax risks and expiring concessions, with BofA forecasting 40% EBITDA drop by 2037 and only 3.5% group EBIT growth.[4]",
        "Muted organic growth across segments and macroeconomic/geopolitical turbulence impacting infrastructure demand.[2][4]"
      ],
      "sources": [
        "https://stockanalysis.com/quote/epa/DG/",
        "https://www.marketscreener.com/news/vinci-shares-jump-after-revenue-increase-record-free-cash-flow-ce7e5ad9d88bf126",
        "https://stockinvest.us/stock/DG.PA",
        "https://www.investing.com/news/analyst-ratings/vinci-stock-downgraded-to-underperform-by-bofa-on-french-tax-risks-93CH-4443975",
        "https://www.morningstar.com/stocks/xpar/dg/quote",
        "https://www.smartkarma.com/home/newswire/earnings-alerts/vinci-sa-dg-earnings-fy-revenue-aligns-with-estimates-and-exceeds-free-cash-flow-expectations/",
        "https://www.vinci.com/en/vinci/page/cours_de_l_action"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "FERG",
      "name": "Ferguson Enterprises Inc.",
      "exchange": "LSE",
      "index": "FTSE100",
      "sector": "Industrials",
      "price": 19170.0,
      "currency": "GBP",
      "market_cap": 38471598080,
      "pe_ratio": 26.260273,
      "forward_pe": 23.252579,
      "roe": 33.404,
      "dividend_yield": 138.0,
      "momentum_6m": 16.616244059754326,
      "momentum_12m": 31.685590830856224,
      "rsi_14": 64.28571428571428,
      "alpha_score": 71,
      "score_breakdown": {
        "value": 9,
        "quality": 22,
        "momentum": 25,
        "catalyst": 5,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/FERG.L",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "Ferguson's strong balance sheet, double-digit non-residential growth (e.g., 21% in Commercial/Mechanical, 14% in Waterworks), and margin expansion demonstrate resilience amid residential headwinds, supported by effective capital allocation and share repurchases.[1][2][3][4] Full-year guidance reaffirms ~5% revenue growth with improved margins, positioning it well for multi-year tailwinds in underbuilt housing and infrastructure projects.[1][3] High ROE (33.4%) and momentum (Alpha Score 71/100) further bolster the outlook despite short-term stock volatility.[3]",
      "company_overview": "Ferguson Enterprises Inc. (FERG) is a leading distributor of plumbing, HVAC, waterworks, and related products primarily in the US and Canada, with a strong market position in non-residential sectors amid residential weakness.[1][2][3] For Q1 fiscal 2026 (ended October 31, 2025), the company reported net sales of $8.2 billion, up 5.1% year-over-year driven by 4.2% organic growth and 1% from acquisitions, alongside gross margin expansion to 30.7% and adjusted operating profit up 14.4% to $808 million.[1][2][3] Despite robust non-residential growth of 12%, residential sales declined 1%, contributing to a post-earnings stock drop of ~4% despite beating revenue and some EPS estimates.[3][4]",
      "key_developments": [
        "Reported Q1 2026 earnings on December 9, 2025, with net sales of $8.2B (+5.1% YoY), adjusted EPS of $2.84 (beat consensus of ~$2.64-$2.77 but missed some higher forecasts of $2.97), and strong non-residential revenue growth of 12% offset by residential declines.[1][2][3][4][7]",
        "Increased quarterly dividend by 7% to $0.89 per share and returned $372M to shareholders via dividends and $208M in repurchases, with $800M remaining in the program; net debt to EBITDA at healthy 1.1x.[1][2][4]",
        "Strategic acquisition of Moore Supply Company to bolster HVAC in Chicago; updated FY2025 guidance to ~5% revenue growth and narrowed operating margins to 9.4-9.6%.[1][3]"
      ],
      "catalysts": [
        "Q2 fiscal 2026 earnings (likely March 2026), with potential for continued non-residential outperformance and margin progress to drive upside.[3][5]",
        "Progress on acquisitions and ~$350M CapEx investments, leveraging structural tailwinds in public works and non-residential projects.[1][3][4]"
      ],
      "risk_factors": [
        "Persistent weakness in residential markets (50% of US sales), driven by soft housing starts, low permits, and RMI activity, potentially pressuring overall growth.[3][4]",
        "Economic uncertainty and market volatility, as seen in post-Q1 stock decline despite beats, with exposure to pricing inflation (~3%) and Canadian segment profit drops.[3][4]"
      ],
      "sources": [
        "https://www.moomoo.com/news/post/62629271/ferguson-enterprises-inc-ferg-q1-2026-earnings-call-transcript-summary",
        "https://quartr.com/companies/ferguson-enterprises-inc_3672",
        "https://www.investing.com/news/company-news/ferguson-q1-2026-slides-eps-miss-triggers-stock-decline-despite-revenue-beat-93CH-4398910",
        "https://www.youtube.com/watch?v=ZKruzocZHyc",
        "https://www.corporate.ferguson.com/investor/events-results-and-reports/default.aspx",
        "https://www.corporate.ferguson.com/investor/why-ferguson/default.aspx",
        "https://www.marketbeat.com/stocks/NYSE/FERG/earnings/",
        "https://www.corporate.ferguson.com/investor/financial-information/sec-filings/default.aspx"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "ENR",
      "name": "Siemens Energy AG",
      "exchange": "XETR",
      "index": "DAX",
      "sector": "Industrials",
      "price": 152.0,
      "currency": "EUR",
      "market_cap": 130012315648,
      "pe_ratio": 95.0,
      "forward_pe": 28.98324,
      "roe": 16.816,
      "dividend_yield": 46.0,
      "momentum_6m": 58.33333333333333,
      "momentum_12m": 166.19965685093595,
      "rsi_14": 71.95574684426185,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 5,
        "quality": 22,
        "momentum": 23,
        "catalyst": 13,
        "liquidity": 7
      },
      "yahoo_url": "https://finance.yahoo.com/quote/ENR.DE",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "Strong momentum from record orders, upgraded guidance through 2028, and broker target hikes to \u20ac164-170 (above current \u20ac152) signal robust execution in grid/energy-transition tailwinds, outweighing high P/E of ~86-95x[1][2][3]. US expansions and \u20ac6bn buyback enhance shareholder returns amid global infrastructure demand[2][6]. Technicals remain supportive with price well above key moving averages and established uptrend[1].",
      "company_overview": "Siemens Energy AG is a Germany-based energy technology company specializing in power generation, grids, renewables, and energy-transition solutions, including gas/steam turbines, high-voltage transmission, wind turbines, and decarbonization technologies like hydrogen production[1][2][3][6]. The firm holds a strong market position amid rising demand for grid infrastructure and energy transition, with record order intake, double-digit revenue growth, and a stock price surging from ~\u20ac14 in early 2024 to \u20ac152 as of early February 2026, delivering +166% 12-month returns[1][3]. Fiscal 2025 results met upgraded guidance, enabling an early dividend payout and share buyback program up to \u20ac6bn by 2028[2][5].",
      "key_developments": [
        "Q4/FY 2025 results released, fulfilling commitments with strong quarterly performance trending toward upper end of guidance; FY2026 outlook set at 11-13% comparable revenue growth and 9-11% profit margin[2].",
        "Raised mid-term targets to FY2028: 14-16% profit margin (from 10-12%) and low-teens% CAGR revenue growth (from high single-digit/low double-digit)[2].",
        "Broker upgrades: Deutsche Bank to \u20ac170 target (from \u20ac135, positive rating) citing improved order pipeline/profitability; Jefferies to \u20ac164 (from \u20ac134, buy) on earnings visibility and grid/energy-transition demand (late Jan/early Feb 2026)[1].",
        "Finalized $1bn US manufacturing expansions to boost capacity[6].",
        "Announced \u20ac0.70 dividend for FY2025, lifting prior ban after exiting federal guarantee, plus investor outreach[2][5]."
      ],
      "catalysts": [
        "FY2026 earnings updates and progress toward upper-end guidance, potentially validating mid-term targets[2].",
        "\u20ac6bn share repurchase execution through 2028 and \u20ac0.70 dividend payments, boosting yields[2][5].",
        "US $1bn expansions ramp-up, supporting order fulfillment in key growth market[6]."
      ],
      "risk_factors": [
        "Elevated valuation (P/E 86-95x vs. sector 24x) leaves room for pullbacks if execution falters or macro sentiment shifts[1][3].",
        "Legacy onshore wind challenges and project execution risks in renewables/gas turbines[1][6]."
      ],
      "sources": [
        "https://capital.com/en-int/analysis/siemens-energy-stock-forecast",
        "https://www.siemens-energy.com/global/en/home/investor-relations.html",
        "https://www.investing.com/equities/siemens-energy-ag",
        "https://www.stockopedia.com/share-prices/siemens-energy-ag-ETR:ENR/news/",
        "https://www.perplexity.ai/finance/ENR.DE",
        "https://www.marketscreener.com/news/siemens-energy-finalizes-1-billion-us-expansions-ce7e5bd2d08af626"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "SAF",
      "name": "Safran SA",
      "exchange": "EPA",
      "index": "CAC40",
      "sector": "Industrials",
      "price": 308.0,
      "currency": "EUR",
      "market_cap": 128284680192,
      "pe_ratio": 29.758453,
      "forward_pe": 29.628347,
      "roe": 34.745997,
      "dividend_yield": 94.0,
      "momentum_6m": 5.987609611503686,
      "momentum_12m": 26.409959646058656,
      "rsi_14": 39.782594994443805,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 5,
        "quality": 25,
        "momentum": 20,
        "catalyst": 13,
        "liquidity": 7
      },
      "yahoo_url": "https://finance.yahoo.com/quote/SAF.PA",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "Safran's strong fundamentals (high ROE 27.93-34.7%, net income \u20ac5.05B) and recent all-time highs signal sustained aerospace demand, trading at a premium but below Morningstar's \u20ac391 fair value.[1][2] Peers like RTX/GE show comparable valuations, supporting quality and momentum (Alpha Score 70/100), though short-term forecasts point to mild pullback to \u20ac296.[1][2]",
      "company_overview": "Safran SA is a leading French aerospace and defense company specializing in aircraft engines, equipment, and propulsion systems, holding a strong market position as a key supplier to major OEMs like Airbus and Boeing. It reports robust financials including \u20ac7.85B in sales revenues, \u20ac5.05B net income, and a market cap of \u20ac126.23B, with shares recently trading around \u20ac305-308 amid a 45.52% yearly gain.[1][4] The stock has shown resilience, hitting all-time highs in late 2025 (e.g., \u20ac305.80 on 2025-10-03) despite a recent dip to \u20ac298.25, the lowest since January 2026.[1]",
      "key_developments": [
        "Shares reached an all-time high of \u20ac305.80 in early October 2025, with 8.83% gains over the prior 4 weeks and 46.97% over 12 months, reflecting strong momentum.[1]",
        "Recent trading (early February 2026) shows volatility: closed at \u20ac308 on Feb 6 (+1.82%), with daily ranges like \u20ac302.50 (Feb 5) to \u20ac305.40 (Feb 3), and a 0.71-3.21% monthly uptick amid broader yearly gains of 45.52%.[1][3][4]",
        "No major operational news in the last 30 days (late Jan to early Feb 2026); focus remains on price action and financial metrics like P/E 9.31-38.74 (varying by source) and ROE ~28-35%.[1][2]"
      ],
      "catalysts": [
        "Q4 2026 earnings and guidance, potentially highlighting engine aftermarket growth amid global travel recovery.",
        "Aerospace sector tailwinds from Airbus/Boeing production ramps and defense spending in Europe/US."
      ],
      "risk_factors": [
        "Short-term price forecasts declining to \u20ac296 (Q4) and \u20ac273 (1-year), signaling potential 3-10% correction from \u20ac308 levels.[1]",
        "High valuation (P/E 29.8-38.74, 546% premium to some models) vulnerable to macro slowdowns in industrials or supply chain issues.[1][2]"
      ],
      "sources": [
        "https://tradingeconomics.com/saf:fp",
        "https://www.morningstar.com/stocks/xpar/saf/quote",
        "https://www.investing.com/equities/safran-historical-data",
        "https://www.safran-group.com/finance/safran-share-price",
        "https://www.safran-group.com/finance/glance",
        "https://finbox.com/ENXTPA:SAF/"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "GSK",
      "name": "GSK plc",
      "exchange": "LSE",
      "index": "FTSE100",
      "sector": "Healthcare",
      "price": 2198.0,
      "currency": "GBP",
      "market_cap": 88211988480,
      "pe_ratio": 15.812949,
      "forward_pe": 11.246936,
      "roe": 43.310001,
      "dividend_yield": 328.0,
      "momentum_6m": 56.58391015225654,
      "momentum_12m": 50.04716990172777,
      "rsi_14": 85.63432835820896,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 13,
        "quality": 19,
        "momentum": 23,
        "catalyst": 5,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/GSK.L",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "GSK plc is a diversified pharmaceutical company with three main divisions: Specialty Medicines (oncology, HIV, respiratory), General Medicines, and Vaccines.[1] The company delivered strong 2025 performance with turnover growth of 4% to \u00a332.6 billion and core operating profit up 11%, driven primarily by double-digit growth in Specialty Medicines across respiratory, immunology, oncology, and HIV segments.[3] Under new CEO Luke Miels (appointed January 2026), GSK is executing a transformation strategy targeting \u00a340 billion in sales by 2031.[1]",
      "company_overview": "GSK plc is a diversified pharmaceutical company with three main divisions: Specialty Medicines (oncology, HIV, respiratory), General Medicines, and Vaccines.[1] The company delivered strong 2025 performance with turnover growth of 4% to \u00a332.6 billion and core operating profit up 11%, driven primarily by double-digit growth in Specialty Medicines across respiratory, immunology, oncology, and HIV segments.[3] Under new CEO Luke Miels (appointed January 2026), GSK is executing a transformation strategy targeting \u00a340 billion in sales by 2031.[1]",
      "key_developments": [
        "**Q4 2025 Results Beat Expectations**: GSK reported Q4 core EPS of 68 cents (beating consensus of 64 cents) and revenue of $11.46 billion (\u00a38.62 billion), exceeding the Zacks estimate of $11.19 billion, with core earnings up 14% at constant exchange rates.[2]"
      ],
      "catalysts": [
        "**2026 Commercial Launches**: Management highlighted 2026 as \"a key year of execution and operational delivery with strong focus on commercial launches,\" suggesting multiple new product introductions could drive incremental growth.[1]"
      ],
      "risk_factors": [
        "**Patent Cliff Risk**: GSK faces loss of lucrative HIV treatment patents from 2028 onwards, creating a significant revenue headwind that specialty medicines growth must offset to maintain trajectory.[6]"
      ],
      "sources": [
        "https://www.nasdaq.com/articles/gsk-q4-results-climb-sees-growth-fy26-backs-2031-sales-view-update",
        "https://www.zacks.com/stock/news/2828654/gsks-q4-earnings-sales-beat-estimates-stock-up-on-26-outlook",
        "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2025-performance-and-re-affirms-long-term-outlooks/",
        "https://www.gurufocus.com/news/8580044/gsk-projects-moderate-growth-in-turnover-and-earnings-by-2026?mobile=true",
        "https://www.ig.com/uk/news-and-trade-ideas/gsk-full-year-earnings--can-the-pharma-giant-deliver-on-post-dem-260203",
        "https://www.voxmarkets.com/articles/gsk-sees-slower-sales-growth-in-2026-as-patent-loss-looms-7c4f7f2",
        "https://www.gsk.com/media/g0lnid23/fy-2025-results-announcement.pdf"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "RIO",
      "name": "Rio Tinto Group",
      "exchange": "LSE",
      "index": "FTSE100",
      "sector": "Basic Materials",
      "price": 6843.0,
      "currency": "GBP",
      "market_cap": 111193030656,
      "pe_ratio": 14.716128,
      "forward_pe": 12.19558,
      "roe": 17.158002,
      "dividend_yield": 416.0,
      "momentum_6m": 49.673994048695945,
      "momentum_12m": 36.53139134072427,
      "rsi_14": 66.68874172185431,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 13,
        "quality": 22,
        "momentum": 25,
        "catalyst": 0,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/RIO.L",
      "signal": "HOLD",
      "confidence": "HIGH",
      "reasoning": "Rio Tinto's diversified portfolio shift toward copper and new assets like Simandou and lithium supports long-term resilience amid stable iron ore volumes, but elevated net debt ($14.6bn at H1 2025), high capex, and overbought technicals (RSI 71.35) limit near-term upside versus analyst targets suggesting overvaluation.[1][2][3][4] Strong financial health (Altman Z-Score 3.67) and dividend policy (40-60% of earnings) provide downside protection, though execution risks in a multi-commodity mix temper enthusiasm for the next 3-6 months.[2][3]",
      "company_overview": "Rio Tinto Group is a leading global mining company focused on iron ore, copper, aluminum, and minerals, with major assets including Pilbara iron ore operations in Australia, a stake in Escondida copper mine, and Oyu Tolgoi in Mongolia.[1][2] In 2024, it reported revenue of $53.66 billion (down 0.71% YoY) and net income of $11.55 billion (up 14.85%), while 2025 saw an 11% copper output increase and slightly lower iron ore shipments.[1] The stock has shown strong momentum with a 6-month return of +49.7% and trades at a P/E of 14.7, though analysts' average price target implies -11.8% downside from recent levels.[1]",
      "key_developments": [
        "Reported Q4 2025 production results with exceptional performance, including 11% higher copper output surpassing guidance and only slightly lower iron ore shipments from Australian mines.[1]",
        "Declined a merger offer from Glencore, prioritizing independence due to disagreements on leadership and valuation, while maintaining strong operating margins (25.39%) and balance sheet (debt-to-equity 0.41).[2]",
        "Released 2026 production guidance: Pilbara iron ore steady at 323-338 Mt, copper at 800-870 kt, initial Simandou sales (5-10 Mt), and new lithium output at 61-64 kt LCE; capex up to ~$11bn.[3]"
      ],
      "catalysts": [
        "Q4/H2 2025 earnings release on February 19, 2026, potentially highlighting copper growth and guidance updates.[1]",
        "Ramp-up progress on Simandou (5-10 Mt sales in 2026) and Oyu Tolgoi underground expansion, boosting volume diversification.[3]",
        "2026 final dividend ex-date, supporting shareholder returns if earnings hold.[5]"
      ],
      "risk_factors": [
        "Commodity price volatility, particularly iron ore weakness or copper realization shortfalls, impacting earnings tied less to single commodities.[3]",
        "Elevated net debt and heavy capex (~$11bn in 2026) pressuring free cash flow if project execution slips or costs rise.[3]",
        "Regulatory/geopolitical challenges in key operations (e.g., Mongolia, Guinea) and overvaluation signals (P/E near 3-year high, fair value \u00a363.89 vs. current ~\u00a368).[2][4]"
      ],
      "sources": [
        "https://stockanalysis.com/stocks/rio/",
        "https://www.gurufocus.com/news/8586961/rio-tinto-rio-declines-offer-maintaining-independence",
        "https://www.ebc.com/forex/is-rio-tinto-stock-a-buy-in-2026-rio-stock-guide",
        "https://simplywall.st/stocks/gb/materials/lse-rio/rio-tinto-group-shares/news/assessing-rio-tinto-lserio-valuation-after-strong-recent-sha",
        "https://www.riotinto.com/en/invest/financial-calendar",
        "https://www.riotinto.com/en/invest/reports",
        "https://www.riotinto.com/en/news/releases"
      ],
      "target_timeframe": "3-6 months"
    },
    {
      "ticker": "AMAT",
      "name": "Applied Materials, Inc.",
      "exchange": "US",
      "index": "NASDAQ_SELECT",
      "sector": "Technology",
      "price": 322.51,
      "currency": "USD",
      "market_cap": 255983124480,
      "pe_ratio": 37.15553,
      "forward_pe": 26.492924,
      "roe": 35.508,
      "dividend_yield": 56.99999999999999,
      "momentum_6m": 75.29524861161806,
      "momentum_12m": null,
      "rsi_14": 48.28819156800613,
      "alpha_score": 70,
      "score_breakdown": {
        "value": 5,
        "quality": 25,
        "momentum": 17,
        "catalyst": 13,
        "liquidity": 10
      },
      "yahoo_url": "https://finance.yahoo.com/quote/AMAT",
      "signal": "BUY",
      "confidence": "HIGH",
      "reasoning": "AMAT benefits from structural tailwinds in AI-driven semiconductor capacity expansion by key customers, with recent analyst upgrades and earnings beats supporting momentum despite high valuation.[1][2] Q1 FY2026 earnings on February 12 could catalyze further upside if results exceed consensus ($2.19 EPS, $6.89B revenue), reinforcing its equipment leadership in a sector trading at elevated multiples.[3][5] While overvalued per some models ($194 fair value), momentum and AI demand outweigh near-term risks in a global capex boom.[2]",
      "company_overview": "Applied Materials, Inc. (AMAT) is a leading supplier of semiconductor manufacturing equipment, serving major chipmakers like TSMC, Intel, and Samsung amid surging demand for AI, cloud computing, and automotive chips.[1][2] The company holds a strong market position in the semiconductor equipment sector, with recent shares surging 6.1% to $322.51 on February 6, 2026, driven by analyst upgrades and a market cap nearing $256 billion; it beat Q4 FY2025 EPS and revenue estimates while guiding Q1 FY2026 EPS at $1.98\u2013$2.38.[1] Fundamentals remain robust with ROE at 39.26%, net margin of 24.67%, and a low debt-to-equity ratio of 0.32, though shares trade at a premium P/E of 37.16 amid 75.3% six-month returns.[1][5]",
      "key_developments": [
        "Shares jumped 6.1% to $322.51 on February 6, 2026, with high volume (8.2M shares), following analyst upgrades including Deutsche Bank to $390 (buy), KeyCorp to $380 (overweight), and Morgan Stanley to $364 (overweight); consensus is Moderate Buy with $315.15 average target.[1]",
        "Recent brokerage reiterated bullish view on February 8, 2026, citing AI chip equipment demand, with shares up 37.19% in three months and 80.97% over one year.[2]",
        "Stock fell 2.96% to $318.67 in a prior session amid broader market weakness, but analysts note positive estimate revisions ahead of February 12 earnings.[5]"
      ],
      "catalysts": [
        "Q1 FY2026 earnings release on February 12, 2026, with potential EPS/revenue beat and guidance on AI/high-performance computing demand.[1][3]",
        "Continued analyst upgrades and sector breakout tied to TSMC/Intel/Samsung fab investments for AI chips.[1][2][4]"
      ],
      "risk_factors": [
        "Year-over-year earnings decline expected (-8% EPS, -3.9% revenue) in Q1, with potential miss pressuring shares post-earnings.[3][5]",
        "US-China export controls on semiconductor equipment and valuation stretch (P/E 37.2, PEG 2.94 vs. industry 2.02), risking pullback if capex slows.[2][5]"
      ],
      "sources": [
        "https://www.marketbeat.com/instant-alerts/applied-materials-nasdaqamat-trading-up-61-whats-next-2026-02-06/",
        "https://simplywall.st/stocks/us/semiconductors/nasdaq-amat/applied-materials/news/a-look-at-applied-materials-amat-valuation-after-bullish-bro",
        "https://www.nasdaq.com/articles/applied-materials-amat-expected-beat-earnings-estimates-can-stock-move-higher",
        "https://www.tikr.com/blog/applied-materials-surged-6-on-equipment-boom-path-to-a-320-breakout-in-2026",
        "https://www.zacks.com/stock/news/2828386/heres-why-applied-materials-amat-fell-more-than-broader-market",
        "https://www.tipranks.com/news/applied-materials-stock-amat-plunges-despite-hopes-for-a-more-constructive-direction"
      ],
      "target_timeframe": "3-6 months"
    }
  ],
  "dashboard_stats": {
    "has_history": true,
    "total_predictions": 20,
    "evaluated": 0,
    "pending": 20,
    "correct": 0,
    "incorrect": 0,
    "inconclusive": 0,
    "win_rate": null,
    "per_signal": {
      "BUY": {
        "total": 0,
        "correct": 0,
        "decisive": 0,
        "accuracy": null,
        "avg_return": null
      },
      "HOLD": {
        "total": 0,
        "correct": 0,
        "decisive": 0,
        "accuracy": null,
        "avg_return": null
      },
      "AVOID": {
        "total": 0,
        "correct": 0,
        "decisive": 0,
        "accuracy": null,
        "avg_return": null
      }
    },
    "weight_overrides": {},
    "active_weights": {
      "value": 25,
      "quality": 25,
      "momentum": 25,
      "catalyst": 15,
      "liquidity": 10
    },
    "base_weights": {
      "value": 25,
      "quality": 25,
      "momentum": 25,
      "catalyst": 15,
      "liquidity": 10
    },
    "recent_evaluations": [],
    "performance_timeline": [
      {
        "date": "2026-02-07",
        "win_rate": null,
        "total_predictions": 20,
        "evaluated": 0,
        "correct": 0,
        "avg_return": null,
        "buy_accuracy": null,
        "hold_accuracy": null,
        "avoid_accuracy": null
      }
    ]
  }
}